Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Monday, MarketBeat Ratings reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 318.41% from the stock’s current price.

Several other research firms also recently commented on ZNTL. William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Wednesday, September 16th. They issued an “outperform” rating for the company. Rodman & Renshaw began coverage on Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price objective on the stock. Mizuho assumed coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 price objective on the stock. Jefferies Financial Group upgraded Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 14th. Finally, Wall Street Zen lowered Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $7.50.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $2.39 on Monday. The company’s 50-day simple moving average is $3.23 and its 200-day simple moving average is $3.86. Zentalis Pharmaceuticals has a 1 year low of $1.21 and a 1 year high of $6.95. The stock has a market capitalization of $171.29 million, a PE ratio of -1.23 and a beta of 1.93.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). On average, sell-side analysts predict that Zentalis Pharmaceuticals will post -2.11 earnings per share for the current year.

Insider Transactions at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters purchased 4,335,000 shares of the stock in a transaction on Friday, August 14th. The stock was bought at an average price of $3.50 per share, for a total transaction of $15,172,500.00. Following the acquisition, the insider directly owned 17,844,973 shares of the company’s stock, valued at approximately $62,457,405.50. The trade was a 32.09% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Spark Investment Management LLC purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth about $61,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at about $126,000. Stonepine Capital Management LLC purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at about $783,678. Seven Fleet Capital Management LP increased its holdings in shares of Zentalis Pharmaceuticals by 188.7% in the 2nd quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company’s stock valued at $1,451,000 after acquiring an additional 207,600 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at about $5,406,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.